Stay Connected With Us:
Welcome to THE PEPTIDE GUIDE

Tesamorelin Dosage and Research Protocol – 10mg

Quickstart Highlights

Tesamorelin is a synthetic analog of Growth Hormone–Releasing Hormone (GHRH) designed to stimulate endogenous growth hormone release and support downstream increases in IGF-1. In research and educational discussions, tesamorelin is commonly associated with lipolysis signaling, metabolic regulation, and protocols focused on visceral fat and body-composition pathways linked to the growth hormone axis.

This educational overview for The Peptide Guide outlines a structured once-daily subcutaneous research-style approach and references a practical dilution strategy intended to support accurate, consistent measurement with standard U-100 insulin syringes.

Tesamorelin Dosage | The Peptide Guide
  • Reconstitution: Add 3.0 mL bacteriostatic water → approximately ~3.33 mg/mL concentration.

  • Standard Daily Dose: 2 mg (2000 mcg) once daily (commonly referenced clinical protocol).

  • Measurement Guide: At 3.33 mg/mL, 1 unit on a U-100 insulin syringe (0.01 mL) ≈ 33.3 mcg.

  • Storage: Store both lyophilized and reconstituted vials refrigerated at 2–8°C.

Dosing & Reconstitution Guide

Standard Protocol (3 mL dilution ≈ 3.33 mg/mL)

What stage are you on?

Choose your stage to instantly see dose and syringe units.

Weekly dose

Units per injection (mL)

Syringe fill level

1020304050600.6 mL
Educational display only. Always follow your clinic, provider, or lab protocol guidance.
🟠⠀Week 1
🟠⠀Weeks 2-12+
🟠⠀Daily Dose: 1 mg / 1000 mcg
🟠⠀Daily Dose: 2 mg / 2000 mcg
🟠⠀30 units
🟠⠀60 units
  • Frequency: Inject subcutaneously once daily.

  • Titration option: A 1-week gradual ramp-up may improve tolerability before moving to the full maintenance dose.

  • Timing: Evening dosing is commonly preferred to better align with natural growth hormone rhythms.

Reconstitution Steps
🟠⠀Draw 3.0 mL bacteriostatic water using a sterile syringe.
🟠⠀Inject slowly down the vial wall to minimize foaming.
🟠⠀Gently swirl until dissolved — avoid shaking vigorously.
🟠⠀Label vial with reconstitution date and concentration.
🟠⠀Store refrigerated at 2–8 °C and protect from light.

Expected timeline: Noticeable changes are often gradual, with early effects commonly reported after a few weeks of consistent daily use. More measurable outcomes typically require several weeks to a couple of months, depending on the individual and the specific research endpoint being tracked.

Important: This content is provided for informational and educational reference only. It is not medical advice, diagnosis, or treatment guidance. Any protocols or dosing discussions are presented strictly in a research context and are not intended for human use recommendations.

Supplies Needed

Estimated supplies for standard daily protocol:

Tesamorelin (10 mg) Vials

  • 8 weeks ≈ 11 vials

  • 12 weeks ≈ 17 vials

  • 16 weeks ≈ 22 vials

U‑100 Insulin Syringes (1 mL)

  • 7 per week (1/day)

  • 8 weeks: 56 syringes

  • 12 weeks: 84 syringes

  • 16 weeks: 112 syringes

Bacteriostatic Water

  • 3.0 mL per vial

Alcohol Swabs

  • 2 per day (vial stopper + injection site)

Protocol Overview

  • Goal: Support reduction of visceral fat and promote metabolic health markers through GH/IGF-1 signaling pathways.

  • Schedule: Daily subcutaneous injections for 12–26 weeks.

  • Dose: 2 mg daily following an initial titration phase.

  • Reconstitution: 3.0 mL per vial to simplify and standardize measurement.

  • Storage: Keep refrigerated before and after reconstitution; avoid repeated freeze–thaw cycles.

Dosing Protocol

Suggested Titration Approach (Tesamorelin)

  • Week 1 (Titration): 1 mg subcutaneous once daily to assess tolerance.

  • Weeks 2+ (Maintenance): 2 mg subcutaneous once daily.

  • Frequency: Once daily (subcutaneous).

  • Cycle Length: 12–26 weeks is commonly referenced; extended protocols have been studied up to 52 weeks in monitored settings.

  • Timing: Evening dosing is often preferred to align with natural growth hormone rhythms.

  • Best Practices: Rotate injection sites regularly for comfort and site hygiene.

Storage Instructions

  • Lyophilized peptide: Store refrigerated at 2–8°C.

  • Formulation note: Some stabilized versions may tolerate short room-temperature storage prior to reconstitution (follow supplier handling guidance).

  • After reconstitution (with bacteriostatic water): Refrigerate at 2–8°C.

  • Do not freeze after mixing: Avoid freezing reconstituted solutions to help preserve peptide integrity.

  • Handling tip: Let the vial reach room temperature before opening to minimize condensation.

Important Notes

  • Use a new, sterile insulin syringe for each injection.

  • Clean the vial stopper and injection site with alcohol prior to administration.

  • Rotate injection sites (abdomen at least 2 inches from the navel, thighs, upper arms).

  • Inject slowly, then pause briefly before withdrawing the needle to reduce leakage.

  • Monitor IGF-1 where applicable, given downstream GH/IGF-1 stimulation effects.

  • If relevant, individuals with metabolic or glucose-regulation concerns should monitor blood glucose.

  • Document daily dosing and injection locations for consistency.

  • Educational / research reference only: Not medical advice; not approved for general therapeutic use outside indicated contexts.

How This Works

Tesamorelin works by mimicking growth hormone–releasing hormone (GHRH) and binding to GHRH receptors in the pituitary, which helps restore a more pulsatile, physiologic pattern of growth hormone release rather than supplying growth hormone directly. The downstream rise in GH drives increased IGF-1 production and influences pathways involved in fat metabolism, nutrient partitioning, and tissue maintenance—including enhanced lipolysis, support for protein synthesis, and broader metabolic signaling effects. In clinical research, tesamorelin has been most consistently associated with reductions in visceral adipose tissue and favorable shifts in certain cardiometabolic markers, while ongoing investigation continues to explore its relevance in metabolic dysfunction and age-related changes in GH/IGF-1 dynamics.

Potential Benefits & Side Effects

Potential Benefits (Educational / Research Context)

  • Reduction of visceral adipose tissue.

  • Improved metabolic and lipid markers.

  • Possible reduction of liver fat in research settings.

  • Support for anabolic metabolic processes related to GH/IGF-1 signaling.

Possible Side Effects

  • Mild injection-site redness, itching, or irritation.

  • Joint or muscle discomfort.

  • Mild fluid retention or peripheral swelling.

  • Occasional tingling sensations sometimes associated with GH-axis activity.

Contraindications (Research Context)

  • Active malignancy.

  • Pregnancy.

  • Known hypersensitivity to peptide components.

Lifestyle Factors

  • Nutrition: Maintain a balanced diet with adequate protein intake to support metabolic and recovery goals.

  • Training: Combine resistance training and aerobic exercise where appropriate for body composition and cardiometabolic support.

  • Sleep: Prioritize consistent sleep timing and duration to support natural GH rhythms.

  • Stress: Manage stress (daily downtime, movement, breathwork, routine) to help maintain overall hormonal balance.

Injection Technique

  • Clean the vial stopper and skin with alcohol and allow both to air dry.

  • Pinch a skinfold, then insert the needle at a 45–90° angle.

  • Inject slowly and steadily; aspiration is not required for subcutaneous injections.

  • Rotate injection sites systematically to help prevent irritation and reduce the risk of lipohypertrophy.

Medical Disclaimer

The information provided on this page is intended for research and educational purposes only. Individuals should consult a qualified healthcare professional before beginning any peptide protocol. Responses may vary between individuals, and appropriate medical supervision is recommended when exploring peptide-based therapies.

Recommended Source

For research consistency and verified quality, The Peptide Guide recommends sourcing Tesamorelin (10 mg) from AminoVault Peptides. When selecting any research supplier, prioritize recent third-party testing, a verified COA, and results from an ISO/IEC 17025–accredited laboratory to support identity confirmation and batch-to-batch consistency.

  • High‑purity peptides with third‑party testing and batch COAs.

  • Transparent documentation aligned with research standards.

  • Professional packaging designed to maintain peptide integrity during shipping.

  • Reliable fulfillment suitable for ongoing research protocols.

Important Notice

This content is provided for informational, educational, and research reference purposes only and does not constitute medical advice, diagnosis, or treatment. Tesamorelin is a prescription medication approved for specific clinical indications, and any therapeutic use should be guided by a licensed medical professional and follow applicable medical standards and prescribing guidelines.

References

Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
— National Institutes of Health, NIDDK (2018)
View Source
Mayo Clinic / IBM Merative (2025)
— Tesamorelin (Subcutaneous route) – Drug Information
View Source
J. Clin. Endocrinol. Metab. (2010)
— Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials
View Source
PLoS ONE (2017)

— Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: A randomized, placebo-controlled trial

View Source
Tesamorelin can improve cognitive function (Research Highlight)
— Nature Reviews Endocrinology (2012)
View Source
Tesamorelin Injection – MedlinePlus Drug Information
— MedlinePlus (U.S. National Library of Medicine) (2025)
View Source
EGRIFTA SV (tesamorelin) – Full Prescribing Information
— Theratechnologies, Inc. (FDA Label) (2024)
View Source
Tesamorelin: Uses, Dosage, Side Effects, Warnings
— Drugs.com (AHFS Monograph & Patient Info) (2025)
View Source
Tesamorelin – LiverTox (Safety Profile)
— NIH NIDDK LiverTox Database (2018)
View Source
Open RN, Chippewa Valley Technical College (2023)

— Administration of Parenteral Medications – Nursing Skills (Open RN Textbook)

View Source
Pure Lab Peptides – Tesamorelin 10 mg Product Page
— Quality and batch documentation for research-grade tesamorelin
View Source
Quick Navigation

Create Your Account Here

Create your account and start your subscription for up to date content and peptide protocols.

Yes! I would like to receive new content and updates.

Stay Connected With Us: